Who are PHYTONADIONE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coumadin, Nadroparin Calcium and Warfarin, Vitamin K1, Standard dose oral anticoagulant, Marevan®, Prothrombin complex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phytonadione.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PHYTONADIONE — Competitive Intelligence Brief

PHYTONADIONE (PHYTONADIONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K [EPC]. Area: Oncology.

marketed Vitamin K [EPC] Vitamin K epoxide reductase complex subunit 1 (VKORC1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PHYTONADIONE (PHYTONADIONE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PHYTONADIONE TARGET	PHYTONADIONE		marketed	Vitamin K [EPC]	Vitamin K epoxide reductase complex subunit 1 (VKORC1)	1982-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Nadroparin Calcium and Warfarin	Nadroparin Calcium and Warfarin	Shanghai Zhongshan Hospital	marketed	Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist)	Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Vitamin K1	Phytonadione	Pfizer Inc.	marketed	Vitamin K [EPC]	Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Marevan®	Marevan®	Federal University of São Paulo	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Prothrombin complex	Prothrombin complex	IRCCS Policlinico S. Donato	marketed	Vitamin K-dependent clotting factor concentrate	Coagulation factors II, VII, IX, X

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K [EPC] class)

· 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PHYTONADIONE — Competitive Intelligence Brief. https://druglandscape.com/ci/phytonadione. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab